Zhejiang Hisun Pharmaceutical Co., Ltd. (SHA:600267)
China · Delayed Price · Currency is CNY 11.84
+0.12 (1.02%)
Jul 29, 2026, 3:00 PM CST
SHA:600267 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 28, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 13,576 | 11,503 | 9,700 | 11,133 | 12,936 | 16,732 | |
Market Cap Growth | -1.72% | 18.59% | -12.87% | -13.94% | -22.69% | 4.84% |
Enterprise Value | 14,190 | 13,638 | 13,151 | 15,743 | 18,163 | 23,563 |
Last Close Price | 11.72 | 9.69 | 7.94 | 8.95 | 10.39 | 13.06 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 28, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 19.64 | 21.28 | 16.14 | - | 26.46 | 34.37 |
Forward PE | 24.94 | 23.27 | 207.50 | 156.00 | 160.67 | 160.67 |
PS Ratio | 1.32 | 1.09 | 0.94 | 1.07 | 1.08 | 1.38 |
PB Ratio | 1.48 | 1.30 | 1.13 | 1.33 | 1.55 | 2.28 |
P/TBV Ratio | 1.67 | 1.48 | 1.31 | 1.58 | 1.92 | 2.84 |
P/FCF Ratio | 7.69 | 6.95 | 4.99 | 8.82 | 8.43 | 15.02 |
P/OCF Ratio | 6.12 | 5.66 | 4.44 | 7.41 | 6.26 | 9.64 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 28, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 1.38 | 1.29 | 1.27 | 1.52 | 1.51 | 1.94 |
EV/EBITDA Ratio | 6.83 | 6.69 | 7.60 | 11.64 | 9.15 | 13.11 |
EV/EBIT Ratio | 12.50 | 12.57 | 20.01 | 49.73 | 18.99 | 27.55 |
EV/FCF Ratio | 8.04 | 8.24 | 6.76 | 12.47 | 11.83 | 21.15 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 28, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.24 | 0.33 | 0.48 | 0.67 | 0.77 | 1.07 |
Debt / EBITDA Ratio | 1.07 | 1.43 | 2.38 | 4.11 | 3.22 | 4.35 |
Debt / FCF Ratio | 1.26 | 1.78 | 2.13 | 4.45 | 4.18 | 7.05 |
Net Debt / Equity Ratio | 0.04 | 0.19 | 0.31 | 0.48 | 0.60 | 0.89 |
Net Debt / EBITDA Ratio | 0.18 | 0.81 | 1.53 | 2.98 | 2.53 | 3.65 |
Net Debt / FCF Ratio | 0.21 | 0.99 | 1.36 | 3.19 | 3.27 | 5.89 |
Asset Turnover | 0.69 | 0.68 | 0.62 | 0.57 | 0.63 | 0.60 |
Inventory Turnover | 3.59 | 3.41 | 3.30 | 3.28 | 3.62 | 3.20 |
Quick Ratio | 0.64 | 0.58 | 0.59 | 0.62 | 0.59 | 0.45 |
Current Ratio | 1.00 | 0.93 | 0.92 | 0.97 | 0.90 | 0.72 |
Return on Equity (ROE) | 7.89% | 6.28% | 6.99% | -1.16% | 6.27% | 6.55% |
Return on Assets (ROA) | 4.76% | 4.37% | 2.45% | 1.09% | 3.13% | 2.66% |
Return on Invested Capital (ROIC) | 7.66% | 6.70% | 4.58% | 2.46% | 5.04% | 4.80% |
Return on Capital Employed (ROCE) | 12.00% | 11.80% | 6.70% | 2.90% | 8.20% | 8.10% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 28, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 5.17% | 4.70% | 6.20% | -0.84% | 3.78% | 2.91% |
FCF Yield | 13.00% | 14.39% | 20.06% | 11.34% | 11.87% | 6.66% |
Dividend Yield | 1.77% | 2.17% | 2.65% | - | 1.64% | 1.07% |
Payout Ratio | 47.04% | 63.51% | 24.70% | - | 77.99% | 85.71% |
Buyback Yield / Dilution | -2.69% | -1.67% | 0.73% | -0.06% | -2.80% | -16.71% |
Total Shareholder Return | -0.92% | 0.50% | 3.38% | -0.06% | -1.16% | -15.63% |